Lead Product(s) : Teduglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : OPKO Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, OPKO will supply its proprietary long-acting GLP-2 peptide and certain Oxyntomodulin analogs, including Teduglutide, the only approved GLP-2 analog, for the development of oral tablet formulations using Entera’s proprietary ora...
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Undisclosed
September 12, 2023
Lead Product(s) : Teduglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : OPKO Biologics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
